Company / Return on Equity (ROE)
Glaukos Corp. Return on Equity (ROE) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Equity (ROE)
-28.6%
FY2025
5-year range
-29.2% / -8.5%
FY2021-FY2025
Trend
-49.8%
vs FY2024
Sector context
#125 of 147
Health Care
What the data says
Glaukos Corp. reports negative total equity of -28.6% in FY2025. Negative equity can occur when accumulated losses exceed contributed capital, as reported in the balance sheet from the SEC filing.
Based on SEC 10-K filings.
-28.6% in FY2025 with a 5-year CAGR of -10.6%.
Remained stable around -28.6% over the past 2 years.
Health Care sector context is included.
Return on Equity (ROE) over time
Growth rates
- 3-Year Change
- -9.9pp
- 5-Year Change
- -10.6pp
- 10-Year Change
- -
Sector benchmark
Bottom 15% in Health CareTop 85% of 147This company -28.6% Sector average -3.1%
▼
-816.5% below sector average
Key checks
Key Insights
- In FY2025, return on equity (roe) decreased 49.8% year-over-year.
- Currently 25.5pp below the Health Care sector average.
- Peak return on equity (roe) was recorded in FY2016.
- Lowest return on equity (roe) in the period was in FY2023.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 0.45 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Equity (ROE)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -28.6% | -49.8% |
| FY2024 | -19.1% | +34.5% |
| FY2023 | -29.2% | -55.8% |
| FY2022 | -18.7% | -121.5% |
| FY2021 | -8.5% | +53.1% |
| FY2020 | -18.0% | -887.3% |
| FY2019 | 2.3% | +130.7% |
| FY2018 | -7.4% | -10542.9% |
| FY2017 | -0.1% | -101.8% |
| FY2016 | 3.9% | +109.9% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026